FDA clears 12-lead, cable-free home ECG monitoring system
The U.S. Food and Drug Administration (FDA) granted 510(k) clearance for the HeartBeam 12-lead electrocardiogram (ECG) synthesis software for the home assessment of arrhythmias. This clearance follows HeartBeam’s successful appeal of a prior "not substantially equivalent (NSE)" determination.
Most consumer home monitoring ECG systems available are single-lead or 6-lead. HeartBeam’s new cable-free technology captures the cardiac electrical signals in three non-coplanar dimensions and synthesizes them into a 12-lead ECG representation. These synthesized 12-lead ECGs also can be reviewed by an on-demand, board-certified cardiologist.
“This FDA clearance is a defining moment for HeartBeam, and the true beginning of our mission to revolutionize cardiac care," HeartBeam CEO Robert Eno said in a statement.
Wearable patch-type ECG monitors are rapidly replacing traditional Holter monitors because of simpler use by patients and the elimination of wired leads. Consumer-grade versions of these types of ECG monitors are also helping capture more cardiac arrhythmia events to improve the diagnosis of various conditions.
“One of the biggest challenges in cardiology is that cardiac symptoms most often don’t happen in the doctor’s office, they happen at home, at night, at work," added Robert A. Harrington, MD, former American Heart Association (AHA) president and a member of the HeartBeam scientific advisory board. "The ability for patients to collect clinically meaningful ECG data at that exact moment, not hours later, can allow physicians to gain a much clearer understanding of a patient’s condition and take more timely action. HeartBeam is designed to be easy to carry and easy for patients to use, representing an important step forward in cardiac care.”
The company said it hopes to begin a limited market launch in early 2026, focusing on select concierge and preventive cardiology groups that have already shown strong interest in adopting the technology. This will enable the company to validate real-world performance and establish reference sites to help expand commercialization.
Eno said a next step is to pursue a FDA heart attack detection indication for the device. He added the company is also developing an on-demand 12-lead extended wear patch and AI-based screening and prediction algorithms.
HeartBeam originally received FDA clearance for its 3D ECG technology for arrhythmia assessment in December 2024. This approval was announced in December 2025.
Numerous cardiology experts clearly see promise with HeartBeam's technology. In addition to Harrington, the company's scientific advisory board includes Peter J. Fitzgerald, Vivek Reddy, Michael Gibson, Tony Das, Niraj Varma, Campbell Rogers and Charles L. Brown III.
Dave Fornell has covered healthcare for more than 17 years, with a focus in cardiology and radiology. Fornell is a 5-time winner of a Jesse H. Neal Award, the most prestigious editorial honors in the field of specialized journalism. The wins included best technical content, best use of social media and best COVID-19 coverage. Fornell was also a three-time Neal finalist for best range of work by a single author. He produces more than 100 editorial videos each year, most of them interviews with key opinion leaders in medicine. He also writes technical articles, covers key trends, conducts video hospital site visits, and is very involved with social media. E-mail: [email protected]